Dashboard
Manage Tickers

NXTC NextCure, Inc.

Nasdaq nextcure.com


$ 11.82 $ 3.23 (37.13 %)    

Friday, 17-Oct-2025 19:21:38 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 11.93
$ 8.60
$ 5.50 x 350
$ 12.00 x 1,000
$ 7.90 - $ 13.17
$ 2.69 - $ 19.20
439,915
na
31.93M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 06-10-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nextcure-doses-first-us-patient-with-sim0505-in-global-phase-1-cancer-trial-targets-proof-of-concept-data-by-1h-2026
NextCure Doses First U.S. Patient With SIM...
10/16/2025 12:09:03

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate...

nextcure-q2-eps-1129-misses-039-estimate
NextCure Q2 EPS $(11.29) Misses $(0.39) Es...
08/07/2025 20:58:18

NextCure (NASDAQ:NXTC) reported quarterly losses of $(11.29) per share which missed the analyst consensus estimate of $(0.39) b...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
07/25/2025 17:07:15

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
07/25/2025 12:08:49

us-stocks-likely-to-open-on-a-mixed-note-intel-philips-66-centene-charter-earnings-in-focus
US Stocks Likely To Open On A Mixed Note: ...
07/25/2025 10:00:10

U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed.

why-deckers-outdoor-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket
Why Deckers Outdoor Shares Are Trading Hig...
07/25/2025 09:36:32

nextcure-stock-skyrockets-nearly-45-in-after-hours-trading-after-sharing-preclinical-data-for-brittle-bone-disease
Nextcure Stock Skyrockets Nearly 45% In Af...
07/25/2025 03:19:51

NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical da...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/24/2025 21:06:08

nextcure-presented-new-preclinical-data-in-a-well-established-model-of-osteogenesis-imperfecta--demonstrating-that-treatment-with-nc605-achieved-improved-bone-microarchitecture-and-reduced-fracture-incidence-compared-to-anti-sclerostin-treatment
NextCure Presented New Preclinical Data In...
07/24/2025 20:11:47

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company com...

piper-sandler-maintains-overweight-on-nextcure-lowers-price-target-to-15
Piper Sandler Maintains Overweight on Next...
07/15/2025 14:41:15

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $3...

nextcure-enacts-1-for-12-reverse-stock-split-shares-begin-trading-today-on-adjusted-basis
NextCure Enacts 1-for-12 Reverse Stock Spl...
07/14/2025 11:19:13

On July 14, 2025, NextCure, Inc., a Delaware corporation (the "Company"), effected a one-for-twelve (1:12) reverse stoc...

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
07/11/2025 23:50:04

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
06/16/2025 17:06:02

nextcure-announced-strategic-partnership-with-simcere-zaiming-to-develop-sim0505-a-cdh6-targeting-antibody-drug-conjugate-for-solid-tumors
NextCure Announced Strategic Partnership W...
06/16/2025 11:06:30

nextcure-and-ligachembio-announces-they-will-present-trial-in-progress-poster-for-lncb74-a-b7-h4-targeted-antibody-drug-conjugate-as-monotherapy-in-participants-with-advanced-solid-tumors-at-american-society-of-clinical-oncology-2025
NextCure And LigaChemBio Announces They Wi...
05/29/2025 20:18:48

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and...

nextcure-q1-eps-039-beats-040-estimate
NextCure Q1 EPS $(0.39) Beats $(0.40) Esti...
05/01/2025 20:57:33

NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.40) by 2...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/09/2025 21:05:58

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
03/19/2025 12:07:12

hc-wainwright--co-reiterates-buy-on-nextcure-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Next...
03/17/2025 15:08:24

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $3 price target.

hc-wainwright--co-reiterates-buy-on-nextcure-lowers-price-target-to-3
HC Wainwright & Co. Reiterates Buy on Next...
03/07/2025 12:26:05

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION